COMMUNIQUÉS West-GlobeNewswire

Mesoblast Corporate Update: Analyst Call
10/09/2019
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an analyst call today. The [...]
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain
10/09/2019
AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular [...]
Interview opportunity: JDRF celebrates the announcement of Dexcom G6 CGM System’s Availability in Canada
10/09/2019
TORONTO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- JDRF shares the excitement of the type 1 diabetes community around today’s arrival of the Dexcom G6 ,” said Dave Prowten, President and CEO of JDRF Canada. “While JDRF remains [...]
Possibilité d’entrevue : FRDJ se réjouit de l’annonce de l’arrivée du système de SGC Dexcom G6 au Canada
10/09/2019
TORONTO, 09 sept. 2019 (GLOBE NEWSWIRE) -- « FRDJ partage l’enthousiasme de la communauté du diabète de type 1 concernant l’ arrivée aujourd’hui du Dexcom G6 », dit Dave Prowten, président et chef de la direction de [...]
BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
09/09/2019
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company [...]
RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit
09/09/2019
September 10 – 12, 2019 Workshops, September 10, 2019 Aloft Boston Seaport District 401-403 D. St., Boston, MA 02210 Executive Chairman/CSO/Interim CEO participating as a workshop leader on Cannabinoid Formulations- [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09/2019
CRESTWOOD, Ky., and WALTHAM Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
OrthoPediatrics Corp. Announces U.S. Launch of Next Generation Cannulated Screw Systems
09/09/2019
WARSAW, Indiana, Sept. 09, 2019 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the U.S [...]
Cerner Executive Jeff Townsend Announces Retirement
09/09/2019
KANSAS CITY, Mo., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cerner Corporation (Nasdaq: CERN) announced today that Jeff Townsend, executive vice president and chief of innovation, will retire by the end of the year, following [...]
Translate Bio Announces Pipeline Program Update
09/09/2019
- Prioritizing and expanding pulmonary disease programs based on early positive cystic fibrosis (CF) data for MRT5005, the first inhaled mRNA therapeutic – - Discontinuing development of MRT5201, a liver-targeted [...]
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
09/09/2019
Flexion’s new locally delivered product candidate, FX301, will combine Xenon’s NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogel FX301 is a potential first-in-class therapy with the aim of providing pain [...]
Mental Health Commission of Canada e-mental health report provides roadmap for reducing wait times and improving care
09/09/2019
From Mental Health Commission of Canada , Government of Newfoundland and Labrador , and Memorial University ST. JOHN’S, Newfoundland and Labrador, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Today, the Mental Health Commission [...]
Un rapport de la Commission de la santé mentale du Canada sur la cybersanté mentale trace la voie pour réduire les temps d’attente et améliorer les soins de santé
09/09/2019
De la Commission de la santé mentale du Canada , du gouvernement de Terre-Neuve-et-Labrador , et de l’Université Memorial ST. JOHN'S, Terre-Neuve-et-Labrador, 09 sept. 2019 (GLOBE NEWSWIRE) -- Aujourd’hui, la Commission [...]
Crossject : Résultats semestriels et point sur l'activité
09/09/2019
Communiqué de Presse Résultats semestriels 2019 et point d’activité Avancées significatives sur le semestre Signature d’un contrat de commercialisation et poursuite des négociations commerciales Confirmation de l’ [...]
Neovacs : 2019 Financial Calendar
09/09/2019
PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, September 9, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and [...]
Néovacs : Agenda financier 2019
09/09/2019
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE Agenda financier 2019 Paris et Boston, le 9 septembre 2019 – 17h45 CEST - Néovacs (Euronext Growth Paris : ALNEV), leader de l'immunothérapie active [...]
Spineway : Notice of the Ordinary and Extraordinary General Shareholders’ Meeting to be held 19 september 2019
09/09/2019
Notice of the Ordinary and Extraordinary General Shareholders’ Meeting to be held 19 september 2019 Arrangements for availability of preparatory documents Spineway’s General Shareholders’ Meeting called for 9 a.m. on 16 [...]
SPINEWAY : Convocation à l'Assemblée Générale Mixte du 19 septembre 2019
09/09/2019
Convocation à l'Assemblée Générale Mixte du 19 septembre 2019 Modalités de mise à disposition des documents préparatoires L'Assemblée Générale des actionnaires de Spineway, convoquée le 16 août 2019 à 9 heures au siège [...]
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME
09/09/2019
Immediate onset of action - starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149. Prolonged durability of [...]

Pages